In 2008, Reven initiated compassionate care use with RJX technology in South Africa for patients with limited to no therapeutic options. This opportunity to aid patients also greatly improved Reven’s understanding of the product, enhancing knowledge in areas of dosing, product stabilization, patient healing trajectories, and outcome analysis.
Reven’s recent drug provision through the Australian Government’s Therapeutic Goods Administration Special Access Scheme and pilot research completed in companion animals has fueled Reven’s knowledge base in support of further investigations into RJXs capacity for multiple treatment modalities.
10+ years of research now including data generated from Reven’s Phase 1 Food and Drug Administration (FDA) approved clinical safety study (ClinicalTrials.gov; ID NCT03680105), continues to provide insight into the capabilities of the RJX technology to promote wellness. Reven intends to further assess these insights in upcoming Phase 2 clinical trials.